Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for PTGX

Stock Name	Protagonist Therapeutics Inc
Ticker	PTGX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US74366E1029

Show aggregate PTGX holdings

News associated with PTGX

Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Barclays: Barclays began coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $72.00 price target on the stock. Several other research firms have also issued reports on PTGX. JMP Securities increased their target price on […] - 2025-09-19 02:36:48
HC Wainwright Reiterates Buy Rating for Protagonist Therapeutics (NASDAQ:PTGX): Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $80.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 28.74% from the stock’s previous close. A number of other […] - 2025-09-19 02:36:47
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at Leerink Partnrs: Leerink Partnrs upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) to a strong-buy rating in a research report released on Friday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Protagonist Therapeutics’ Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($1.95) EPS. A number of other analysts […] - 2025-09-15 02:47:57
We Did The Math IJR Can Go To $133: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-28 09:18:11
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Mutual of America Capital Management LLC: Mutual of America Capital Management LLC decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 3.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 8,679 shares of the company’s stock after selling 348 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Protagonist Therapeutics were […] - 2025-08-13 05:45:10
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of “Buy” by Analysts: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation […] - 2025-08-08 04:42:56
Jefferies Financial Group Inc. Sells 857,602 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Jefferies Financial Group Inc. lessened its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 57.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 631,893 shares of the company’s stock after selling 857,602 shares during the period. Jefferies Financial Group Inc.’s holdings in Protagonist Therapeutics were worth $30,558,000 as of […] - 2025-08-01 05:38:53
Royce & Associates LP Buys New Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Royce & Associates LP bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,255 shares of the company’s stock, valued at approximately $593,000. A number of other hedge funds […] - 2025-07-30 04:49:05
XSMO's Underlying Holdings Could Mean 15% Gain Potential: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 08:27:31
Dinesh V. Ph D. Patel Sells 12,859 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 12,859 shares of the company’s stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $54.86, for a total value of $705,444.74. Following the sale, the chief executive officer owned 570,603 shares in […] - 2025-07-25 06:28:57
Dinesh V. Ph D. Patel Sells 17,520 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 17,520 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $54.79, for a total transaction of $959,920.80. Following the transaction, the chief executive officer owned 531,018 shares in the […] - 2025-07-25 05:42:54
Massachusetts Financial Services Co. MA Sells 723 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Massachusetts Financial Services Co. MA trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,726 shares of the company’s stock after selling 723 shares […] - 2025-07-21 05:51:00
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Lowered by Teacher Retirement System of Texas: Teacher Retirement System of Texas trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 8.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,025 shares of the company’s stock after selling 1,074 shares during the period. Teacher Retirement System […] - 2025-07-16 04:34:43
Amalgamated Bank Sells 467 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Amalgamated Bank cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,938 shares of the company’s stock after selling 467 shares during the quarter. Amalgamated Bank’s holdings […] - 2025-07-10 05:10:51
GAMMA Investing LLC Has $58,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): GAMMA Investing LLC grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 153.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,203 shares of the company’s stock after buying an additional 728 shares during the period. GAMMA Investing […] - 2025-07-10 04:14:49
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of “Buy” from Analysts: Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the […] - 2025-07-09 04:43:49
Oregon Public Employees Retirement Fund Has $663,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Oregon Public Employees Retirement Fund cut its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 13,700 shares of the company’s stock after selling 300 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in […] - 2025-07-08 05:24:51
Illinois Municipal Retirement Fund Sells 14,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Illinois Municipal Retirement Fund cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 41.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 19,509 shares of the company’s stock after selling 14,000 shares during the period. Illinois Municipal Retirement Fund’s holdings in Protagonist Therapeutics were worth $943,000 as of […] - 2025-07-02 05:28:54
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by California State Teachers Retirement System: California State Teachers Retirement System cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 42,349 shares of the company’s stock after selling 316 shares during the quarter. California State Teachers Retirement System’s holdings in Protagonist Therapeutics were worth […] - 2025-06-09 05:00:56
Tidal Investments LLC Decreases Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Tidal Investments LLC trimmed its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 21,012 shares of the company’s stock after selling 1,050 shares during the period. Tidal Investments LLC’s holdings in Protagonist Therapeutics were worth $811,000 at the end of the most […] - 2025-05-27 05:22:57
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44: Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have been given an average recommendation of “Buy” by the nine research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-05-23 03:14:53
Protagonist Therapeutics (NASDAQ:PTGX) Earns “Buy” Rating from HC Wainwright: Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $80.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 71.64% from the stock’s previous close. Other equities research analysts […] - 2025-05-21 03:03:18
Deutsche Bank AG Acquires 17,763 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Deutsche Bank AG increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 137,932 shares of the company’s stock after purchasing an additional 17,763 shares during […] - 2025-05-19 05:10:57
Comerica Bank Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Comerica Bank decreased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 20,558 shares of the company’s stock after selling 346 shares during the period. Comerica Bank’s holdings in Protagonist Therapeutics were worth $794,000 at the end of the most […] - 2025-05-14 05:20:53
Marshall Wace LLP Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Marshall Wace LLP trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 93.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,716 shares of the company’s stock after selling 295,657 shares during the quarter. […] - 2025-05-02 05:30:50
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Mariner LLC: Mariner LLC increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 12.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,983 shares of the company’s stock after buying an additional 2,004 shares during the period. Mariner LLC’s holdings in Protagonist Therapeutics were worth […] - 2025-04-30 05:19:01
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44: Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation […] - 2025-04-28 02:22:54
Barclays PLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Barclays PLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 126,733 shares of the company’s stock after selling 262 shares during the period. Barclays PLC’s holdings in Protagonist Therapeutics were worth $4,891,000 as of its most recent SEC filing. A […] - 2025-04-27 05:24:54
Bank of Montreal Can Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Bank of Montreal Can grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,250 shares of the company’s stock after acquiring an additional 270 shares during the quarter. Bank of Montreal Can’s holdings in Protagonist Therapeutics were worth $241,000 […] - 2025-04-25 04:36:55
Geode Capital Management LLC Acquires 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX): Geode Capital Management LLC raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,377,063 shares of the company’s stock after purchasing an additional 2,366 shares during the quarter. […] - 2025-04-14 05:00:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc PTGX holdings

Date	Number of PTGX Shares Held	Base Market Value of PTGX Shares	Local Market Value of PTGX Shares	Change in PTGX Shares Held	Change in PTGX Base Value	Current Price per PTGX Share Held	Previous Price per PTGX Share Held
2025-12-11 (Thursday)	23,769	USD 2,192,690	USD 2,192,690	0	USD 20,679	USD 92.25	USD 91.38
2025-12-10 (Wednesday)	23,769	USD 2,172,011	USD 2,172,011	0	USD 67,028	USD 91.38	USD 88.56
2025-12-09 (Tuesday)	23,769	USD 2,104,983	USD 2,104,983	0	USD -40,169	USD 88.56	USD 90.25
2025-12-08 (Monday)	23,769	USD 2,145,152	USD 2,145,152	0	USD 14,261	USD 90.25	USD 89.65
2025-12-05 (Friday)	23,769	USD 2,130,891	USD 2,130,891	0	USD 55,144	USD 89.65	USD 87.33
2025-12-04 (Thursday)	23,769	USD 2,075,747	USD 2,075,747	0	USD 29,949	USD 87.33	USD 86.07
2025-12-03 (Wednesday)	23,769	USD 2,045,798	USD 2,045,798	-415	USD -1,378	USD 86.07	USD 84.65
2025-12-02 (Tuesday)	24,184	USD 2,047,176	USD 2,047,176	166	USD -9,726	USD 84.65	USD 85.64
2025-12-01 (Monday)	24,018	USD 2,056,902	USD 2,056,902	0	USD -104,718	USD 85.64	USD 90
2025-11-28 (Friday)	24,018	USD 2,161,620	USD 2,161,620	0	USD -1,681	USD 90	USD 90.07
2025-11-27 (Thursday)	24,018	USD 2,163,301	USD 2,163,301	0	USD 0	USD 90.07	USD 90.07
2025-11-26 (Wednesday)	24,018	USD 2,163,301	USD 2,163,301	0	USD 5,044	USD 90.07	USD 89.86

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PTGX by Blackrock for IE00B3VWM098

Show aggregate share trades of PTGX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-03 SELL -415 87.100 84.730 84.967 USD -35,261 52.95 Loss of -13,286 on sale
2025-12-02 BUY 166 86.390 83.520 83.807 USD 13,912 52.80
2025-11-25 SELL -249 89.880 87.760 87.972 USD -21,905 51.92 Loss of -8,978 on sale
2025-11-24 BUY 3,004 88.335 85.745 86.004 USD 258,356 51.74
2025-11-17 SELL -803 85.450 82.790 83.056 USD -66,694 50.91 Loss of -25,813 on sale
2025-11-12 SELL -73 84.850* 50.40 Profit of 3,679 on sale
2025-11-06 SELL -73 79.920 77.000 77.292 USD -5,642 49.74 Loss of -2,011 on sale
2025-11-05 SELL -730 78.120 75.640 75.888 USD -55,398 49.59 Loss of -19,194 on sale
2025-11-04 SELL -146 78.010 75.440 75.697 USD -11,052 49.45 Loss of -3,832 on sale
2025-11-03 SELL -146 80.430 75.535 76.025 USD -11,100 49.31 Loss of -3,900 on sale
2025-10-28 BUY 219 78.510 78.780 78.753 USD 17,247 48.69
2025-10-24 SELL -73 74.860 75.525 75.459 USD -5,508 48.41 Loss of -1,975 on sale
2025-10-15 BUY 438 77.680 78.150 78.103 USD 34,209 47.32
2025-10-02 BUY 73 64.980 65.500 65.448 USD 4,778 47.12
2025-09-30 BUY 146 66.430 67.040 66.979 USD 9,779 46.91
2025-08-21 SELL -81 56.040 56.470 56.427 USD -4,571 46.44 Loss of -809 on sale
2025-07-31 BUY 240 53.860 55.290 55.147 USD 13,235 46.34
2025-06-30 SELL -162 55.270 57.235 57.039 USD -9,240 45.42 Loss of -1,883 on sale
2025-06-25 SELL -81 54.440 54.955 54.904 USD -4,447 45.21 Loss of -785 on sale
2025-06-20 SELL -162 53.340 54.970 54.807 USD -8,879 45.04 Loss of -1,583 on sale
2025-05-30 BUY 3,728 47.470 47.740 47.713 USD 177,874 43.99
2025-05-23 BUY 67 45.660 45.990 45.957 USD 3,079 43.90
2025-05-19 SELL -67 45.570 45.580 45.579 USD -3,054 43.83 Loss of -117 on sale
2025-05-15 SELL -201 44.410 44.760 44.725 USD -8,990 43.82 Loss of -183 on sale
2025-05-12 SELL -67 45.270 45.830 45.774 USD -3,067 43.80 Loss of -132 on sale
2025-05-09 SELL -67 42.970 45.430 45.184 USD -3,027 43.81 Loss of -92 on sale
2025-04-30 SELL -67 45.820 46.015 45.995 USD -3,082 43.78 Loss of -149 on sale
2025-04-24 SELL -134 44.850 46.060 45.939 USD -6,156 43.73 Loss of -295 on sale
2025-04-17 SELL -67 46.280 46.870 46.811 USD -3,136 43.61 Loss of -214 on sale
2025-04-15 SELL -201 46.950 48.320 48.183 USD -9,685 43.55 Loss of -931 on sale
2025-04-14 SELL -201 45.030 45.510 45.462 USD -9,138 43.53 Loss of -388 on sale
2025-04-09 SELL -268 42.570 43.910 43.776 USD -11,732 43.58 Loss of -51 on sale
2025-04-07 SELL -469 43.210 45.320 45.109 USD -21,156 43.61 Loss of -702 on sale
2025-04-04 SELL -670 44.440 46.450 46.249 USD -30,987 43.60 Loss of -1,774 on sale
2025-03-31 BUY 67 48.360 48.800 48.756 USD 3,267 43.45
2025-03-19 SELL -134 54.350 54.540 54.521 USD -7,306 42.58 Loss of -1,600 on sale
2025-03-14 SELL -402 54.780 55.390 55.329 USD -22,242 42.10 Loss of -5,319 on sale
2025-03-13 SELL -134 54.900 58.700 58.320 USD -7,815 41.91 Loss of -2,198 on sale
2025-03-12 SELL -2,278 57.650 60.600 60.305 USD -137,375 41.69 Loss of -42,414 on sale
2025-03-07 SELL -134 38.350 39.900 39.745 USD -5,326 41.25 Profit of 201 on sale
2025-03-06 SELL -201 39.050 39.400 39.365 USD -7,912 41.28 Profit of 385 on sale
2025-03-03 SELL -67 38.500 42.510 42.109 USD -2,821 41.41 Loss of -47 on sale
2025-02-28 SELL -5,522 37.590 37.660 37.653 USD -207,920 41.48 Profit of 21,109 on sale
2025-02-26 SELL -81 36.150 36.250 36.240 USD -2,935 41.65 Profit of 438 on sale
2025-02-25 SELL -243 35.090 36.820 36.647 USD -8,905 41.77 Profit of 1,244 on sale
2025-02-18 BUY 405 37.750 39.100 38.965 USD 15,781 42.13
2025-02-13 BUY 81 38.680 38.720 38.716 USD 3,136 42.34
2025-02-12 BUY 81 37.420 37.540 37.528 USD 3,040 42.44
2025-02-11 BUY 243 36.990 38.010 37.908 USD 9,212 42.55
2025-02-06 BUY 729 37.750 39.310 39.154 USD 28,543 42.84
2025-01-27 BUY 81 38.360 39.890 39.737 USD 3,219 43.87
2024-12-30 BUY 405 38.510 38.850 38.816 USD 15,720 44.55
2024-12-06 BUY 324 42.060 42.765 42.694 USD 13,833 44.86
2024-12-05 BUY 81 41.680 43.050 42.913 USD 3,476 44.97
2024-12-04 BUY 405 40.580 42.180 42.020 USD 17,018 45.13
2024-11-29 BUY 405 43.800 45.258 45.112 USD 18,270 45.42
2024-11-27 BUY 324 44.950 45.600 45.535 USD 14,753 45.46
2024-11-26 BUY 81 44.830 46.515 46.346 USD 3,754 45.48
2024-11-21 BUY 405 41.650 43.380 43.207 USD 17,499 45.63
2024-11-20 BUY 243 40.650 41.180 41.127 USD 9,994 45.91
2024-11-18 BUY 972 40.390 41.050 40.984 USD 39,836 46.71
2024-11-12 BUY 648 43.170 46.640 46.293 USD 29,998 46.94
2024-11-08 BUY 405 46.230 48.860 48.597 USD 19,682 46.99
2024-11-07 BUY 1,215 47.610 48.690 48.582 USD 59,027 46.95
2024-11-06 BUY 162 47.600 48.670 48.563 USD 7,867 46.89
2024-10-31 BUY 81 45.840 47.320 47.172 USD 3,821 47.18
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-03	SELL	-415	87.100	84.730	84.967	USD -35,261	52.95 Loss of -13,286 on sale
2025-12-02	BUY	166	86.390	83.520	83.807	USD 13,912	52.80
2025-11-25	SELL	-249	89.880	87.760	87.972	USD -21,905	51.92 Loss of -8,978 on sale
2025-11-24	BUY	3,004	88.335	85.745	86.004	USD 258,356	51.74
2025-11-17	SELL	-803	85.450	82.790	83.056	USD -66,694	50.91 Loss of -25,813 on sale
2025-11-12	SELL	-73			84.850*		50.40 Profit of 3,679 on sale
2025-11-06	SELL	-73	79.920	77.000	77.292	USD -5,642	49.74 Loss of -2,011 on sale
2025-11-05	SELL	-730	78.120	75.640	75.888	USD -55,398	49.59 Loss of -19,194 on sale
2025-11-04	SELL	-146	78.010	75.440	75.697	USD -11,052	49.45 Loss of -3,832 on sale
2025-11-03	SELL	-146	80.430	75.535	76.025	USD -11,100	49.31 Loss of -3,900 on sale
2025-10-28	BUY	219	78.510	78.780	78.753	USD 17,247	48.69
2025-10-24	SELL	-73	74.860	75.525	75.459	USD -5,508	48.41 Loss of -1,975 on sale
2025-10-15	BUY	438	77.680	78.150	78.103	USD 34,209	47.32
2025-10-02	BUY	73	64.980	65.500	65.448	USD 4,778	47.12
2025-09-30	BUY	146	66.430	67.040	66.979	USD 9,779	46.91
2025-08-21	SELL	-81	56.040	56.470	56.427	USD -4,571	46.44 Loss of -809 on sale
2025-07-31	BUY	240	53.860	55.290	55.147	USD 13,235	46.34
2025-06-30	SELL	-162	55.270	57.235	57.039	USD -9,240	45.42 Loss of -1,883 on sale
2025-06-25	SELL	-81	54.440	54.955	54.904	USD -4,447	45.21 Loss of -785 on sale
2025-06-20	SELL	-162	53.340	54.970	54.807	USD -8,879	45.04 Loss of -1,583 on sale
2025-05-30	BUY	3,728	47.470	47.740	47.713	USD 177,874	43.99
2025-05-23	BUY	67	45.660	45.990	45.957	USD 3,079	43.90
2025-05-19	SELL	-67	45.570	45.580	45.579	USD -3,054	43.83 Loss of -117 on sale
2025-05-15	SELL	-201	44.410	44.760	44.725	USD -8,990	43.82 Loss of -183 on sale
2025-05-12	SELL	-67	45.270	45.830	45.774	USD -3,067	43.80 Loss of -132 on sale
2025-05-09	SELL	-67	42.970	45.430	45.184	USD -3,027	43.81 Loss of -92 on sale
2025-04-30	SELL	-67	45.820	46.015	45.995	USD -3,082	43.78 Loss of -149 on sale
2025-04-24	SELL	-134	44.850	46.060	45.939	USD -6,156	43.73 Loss of -295 on sale
2025-04-17	SELL	-67	46.280	46.870	46.811	USD -3,136	43.61 Loss of -214 on sale
2025-04-15	SELL	-201	46.950	48.320	48.183	USD -9,685	43.55 Loss of -931 on sale
2025-04-14	SELL	-201	45.030	45.510	45.462	USD -9,138	43.53 Loss of -388 on sale
2025-04-09	SELL	-268	42.570	43.910	43.776	USD -11,732	43.58 Loss of -51 on sale
2025-04-07	SELL	-469	43.210	45.320	45.109	USD -21,156	43.61 Loss of -702 on sale
2025-04-04	SELL	-670	44.440	46.450	46.249	USD -30,987	43.60 Loss of -1,774 on sale
2025-03-31	BUY	67	48.360	48.800	48.756	USD 3,267	43.45
2025-03-19	SELL	-134	54.350	54.540	54.521	USD -7,306	42.58 Loss of -1,600 on sale
2025-03-14	SELL	-402	54.780	55.390	55.329	USD -22,242	42.10 Loss of -5,319 on sale
2025-03-13	SELL	-134	54.900	58.700	58.320	USD -7,815	41.91 Loss of -2,198 on sale
2025-03-12	SELL	-2,278	57.650	60.600	60.305	USD -137,375	41.69 Loss of -42,414 on sale
2025-03-07	SELL	-134	38.350	39.900	39.745	USD -5,326	41.25 Profit of 201 on sale
2025-03-06	SELL	-201	39.050	39.400	39.365	USD -7,912	41.28 Profit of 385 on sale
2025-03-03	SELL	-67	38.500	42.510	42.109	USD -2,821	41.41 Loss of -47 on sale
2025-02-28	SELL	-5,522	37.590	37.660	37.653	USD -207,920	41.48 Profit of 21,109 on sale
2025-02-26	SELL	-81	36.150	36.250	36.240	USD -2,935	41.65 Profit of 438 on sale
2025-02-25	SELL	-243	35.090	36.820	36.647	USD -8,905	41.77 Profit of 1,244 on sale
2025-02-18	BUY	405	37.750	39.100	38.965	USD 15,781	42.13
2025-02-13	BUY	81	38.680	38.720	38.716	USD 3,136	42.34
2025-02-12	BUY	81	37.420	37.540	37.528	USD 3,040	42.44
2025-02-11	BUY	243	36.990	38.010	37.908	USD 9,212	42.55
2025-02-06	BUY	729	37.750	39.310	39.154	USD 28,543	42.84
2025-01-27	BUY	81	38.360	39.890	39.737	USD 3,219	43.87
2024-12-30	BUY	405	38.510	38.850	38.816	USD 15,720	44.55
2024-12-06	BUY	324	42.060	42.765	42.694	USD 13,833	44.86
2024-12-05	BUY	81	41.680	43.050	42.913	USD 3,476	44.97
2024-12-04	BUY	405	40.580	42.180	42.020	USD 17,018	45.13
2024-11-29	BUY	405	43.800	45.258	45.112	USD 18,270	45.42
2024-11-27	BUY	324	44.950	45.600	45.535	USD 14,753	45.46
2024-11-26	BUY	81	44.830	46.515	46.346	USD 3,754	45.48
2024-11-21	BUY	405	41.650	43.380	43.207	USD 17,499	45.63
2024-11-20	BUY	243	40.650	41.180	41.127	USD 9,994	45.91
2024-11-18	BUY	972	40.390	41.050	40.984	USD 39,836	46.71
2024-11-12	BUY	648	43.170	46.640	46.293	USD 29,998	46.94
2024-11-08	BUY	405	46.230	48.860	48.597	USD 19,682	46.99
2024-11-07	BUY	1,215	47.610	48.690	48.582	USD 59,027	46.95
2024-11-06	BUY	162	47.600	48.670	48.563	USD 7,867	46.89
2024-10-31	BUY	81	45.840	47.320	47.172	USD 3,821	47.18

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PTGX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	204,101	2,581	524,512	38.9%
2025-09-18	261,238	603	538,967	48.5%
2025-09-17	160,871	455	278,662	57.7%
2025-09-16	119,487	213	179,491	66.6%
2025-09-15	164,481	90	265,275	62.0%
2025-09-12	129,277	1,000	230,328	56.1%
2025-09-11	242,764	0	391,638	62.0%
2025-09-10	158,669	1,425	254,846	62.3%
2025-09-09	425,476	500	622,218	68.4%
2025-09-08	528,123	800	611,363	86.4%
2025-09-05	518,633	11,824	804,839	64.4%
2025-09-04	337,385	2,916	576,292	58.5%
2025-09-03	195,570	1,053	372,182	52.5%
2025-09-02	188,399	0	271,348	69.4%
2025-08-29	165,571	500	265,840	62.3%
2025-08-28	272,112	902	423,847	64.2%
2025-08-27	322,274	11,729	514,925	62.6%
2025-08-26	67,797	3	206,573	32.8%
2025-08-25	108,118	1,807	147,926	73.1%
2025-08-22	92,580	0	136,504	67.8%
2025-08-21	67,903	732	226,490	30.0%
2025-08-20	137,747	4,436	275,169	50.1%
2025-08-19	108,591	2,229	172,546	62.9%
2025-08-18	145,066	89	190,752	76.0%
2025-08-15	102,863	1,000	136,937	75.1%
2025-08-14	166,263	0	194,337	85.6%
2025-08-13	142,989	4,887	265,978	53.8%
2025-08-12	119,666	1,400	138,812	86.2%
2025-08-11	161,809	0	224,270	72.1%
2025-08-08	126,345	380	200,061	63.2%
2025-08-07	250,926	10	327,014	76.7%
2025-08-06	118,632	274	136,885	86.7%
2025-08-05	95,352	5	128,071	74.5%
2025-08-04	107,663	3,147	140,665	76.5%
2025-08-01	102,643	0	185,382	55.4%
2025-07-31	134,674	26,403	236,093	57.0%
2025-07-30	88,986	1,477	128,497	69.3%
2025-07-29	108,417	242	253,165	42.8%
2025-07-28	195,264	19	241,347	80.9%
2025-07-25	117,334	156	198,470	59.1%
2025-07-24	191,250	125	255,624	74.8%
2025-07-23	393,783	53	542,672	72.6%
2025-07-22	117,379	20,048	158,451	74.1%
2025-07-21	92,245	93	135,809	67.9%
2025-07-18	93,308	98	145,564	64.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE